ArticleCurrent oncology (Toronto, Ont.)2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Mustafa Seyyar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.